KalVista's Sebetralstat Data Shows Shift to Oral HAE Treatment
Event summary
- KalVista presented new data at AAAAI and WSAAI showing high patient satisfaction and evolving treatment trends with EKTERLY® (sebetralstat) for hereditary angioedema (HAE).
- As of July 9, 2025, 2,464 HAE attacks were treated with sebetralstat, with 83.1% of attacks rated as satisfied or better.
- Use of conventional injectable treatments within 12 hours decreased to 5.1% of attacks, showing a decreasing trend with repeated sebetralstat use.
- 98.1% of attacks were treated using either oral sebetralstat (82.1%) or conventional injectable on-demand treatment (16%).
- Treating HAE attacks within 30 minutes of onset was the strongest predictor of achieving earlier symptom relief with sebetralstat.
The big picture
KalVista's data underscores a significant shift in HAE management towards oral therapies, potentially transforming the treatment landscape. The high patient satisfaction and preference for sebetralstat suggest a growing acceptance of oral on-demand treatments, which could drive broader adoption and market expansion. The strategic focus on early intervention and sustained efficacy positions EKTERLY as a potential foundational therapy for HAE management worldwide.
What we're watching
- Regulatory Approvals
- Whether KalVista can secure additional regulatory approvals for sebetralstat in key global markets, including the planned US filing for children aged 2–11 in 2026.
- Market Penetration
- The pace at which sebetralstat can displace conventional injectable treatments for HAE, given the observed shift in treatment patterns and high patient satisfaction.
- Clinical Efficacy
- How the sustained effectiveness and high patient satisfaction with repeated use of sebetralstat will impact long-term adherence and market adoption.